Streetwise Reports' Article Archives — Current Month (47)

Uranium Price Forecast 2022, Growth Expected (01/17/2022)

Political unrest in Kazakhstan and a buildup of stockpiles is leading to tightened demand and opportunities for growth in uranium, according to an industry report.

more>

Shades of Great Bear in Metals Creek (01/17/2022)

With two strong projects in a Tier One jurisdiction and experienced management and geological teams, Metals Creek Resources Ltd. could be ready for a breakout.

more>

This Pharmaceutical Company Has a Brilliant Concept (01/17/2022)

Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. The company currently has a market cap of US$11.25M, $2M cash in the bank, and several promising late-stage drugs — and it is bound for the NASDAQ. Its closest competitors working on similar illnesses and at similar stages have market caps between $91 and $660 million. Catalysts abound with this genius repurposing company.

more>

Hydrogen Stock at Great Entry Point (01/17/2022)

Following a severe downtrend, charts show Jericho Energy Ventures Inc. could be about to take off, analyst Clive Maund says.

more>

Uranium Explorer Expecting Drill Results Soon (01/16/2022)

The Critical Investor discusses the latest developments for Blue Sky Uranium with CEO Niko Cacos, as a new drill program at Ivana has commenced, and the company has won a lawsuit.

more>

BC Junior Looks to Boost Status in Golden Triangle (01/15/2022)

If your neighbors sell their house, the sale price will tell you a lot about the value of your home. In British Columbia’s Golden Triangle, companies with mines and well-defined resource development plans are getting taken out and the remaining players — and their investors — can see the favorable writing on the wall.

more>

Semiconductor Sales Forecast Third Straight Year of Growth on Tight Supplies, Global Digital Transformation (01/15/2022)

After semiconductor sales shattered records in 2021 amid an ongoing supply shortage, chip manufacturers are forecasting another year of growth in 2022. An overwhelming digital transformation is expected to ramp up this year across multiple industries, which could subsequently bring over half a trillion dollars to the semiconductor industry, writes McAlinden Research Partners.

more>

Lithium Mining Co. Expands Asset Portfolio in New Deal (01/14/2022)

The Critical Investor provides a quick update about Argentina Lithium, after they announced the acquisition of more lithium projects, on the back of a C$6M raise. All this when lithium product prices are breaking record after record.

more>

Sell-Side Research Started On Copper Mining Co. (01/13/2022)

World Copper continues to execute its strategy of acquiring and advancing copper projects, with lots of work planned for 2022, noted a Zacks Small-Cap Research report.

more>

A Critical Q & A With Kenorland Minerals CEO Zach Flood (01/13/2022)

After Kenorland Minerals announced its latest batch of drill results, the Critical Investor took the opportunity to do an extensive interview with CEO Zach Flood to discuss results, programs, strategy, and projects for 2022.

more>

Leading Low-Cost Homebuilder Posts 71% Increase in Q4 EPS (01/13/2022)

Shares of leading homebuilder KB Home rose 16% after the company reported Q4/21 and FY/21 financial results that included substantial increases in revenues and margins fueled by rising sales prices and demand for new homes nationwide.

more>

Successful Junior Miner Sees Cash Flow (01/13/2022)

Michael Sheikh explains what makes Guanajuato Silver Co. a unique opportunity and takes a look at five other companies that caught his eye.

more>

Get Ballanger's Top Picks for 2022 (01/12/2022)

Sector expert Michael Ballanger finds himself at an investing crossroads. Find out what his top picks are for 2022.

more>

Goliath Nails High-Grade Gold in 24 Out of 24 Holes, Stock Declines (01/12/2022)

Bob Moriarty of 321Gold shares his thoughts on Goliath Resources' outstanding drill results, which they just announced on Tuesday.

more>

Progress at Several Top Resource Companies (01/12/2022)

In this update, Adrian Day discusses some recent developments that occurred over the holidays, or otherwise got lost in the shuffle.

more>

Ph1 Trial Results of Dementia Drug Positive (01/12/2022)

Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.

more>

Cell Firm Joins With Food Co. to Create Meat Substitute (01/12/2022)

Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report.

more>

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial (01/12/2022)

Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study.

more>

Newrange Expands Gold Search in 2022 (01/11/2022)

Newrange Gold Corp. is expanding its search for precious minerals from one project to three in 2022 and looking at the big picture at its flagship operation in Nevada.

more>

Media Co. Gets New Listing on CSE (01/11/2022)

Mijem Newcomm Tech is going public to capitalize on the cryptocurrencies trend, given it now rewards users of its marketplace app with Bitcoin SV.

more>

Financial Firm Recommends Royalty and Streaming Cos. (01/11/2022)

These companies are attractive now because, unlike mining operators, they are insulated from inflationary costs, noted a BMO Capital Markets report.

more>

Bitcoin Miner Announces Q4/21 Production, 2022 Outlook (01/11/2022)

COVID and supply chain constraints hampered its Q4/21 production, but Riot Blockchain is bullish on its 2022 performance, noted a ROTH Capital Partners report.

more>

Biotech Co. Partners With Life Sciences Firms (01/11/2022)

2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

more>

Analyst Stands at Crossroads in 2022 (01/11/2022)

With the accelerating involvement of government in the day-to-day behavior of all markets, it's a near-impossibility to forecast what will happen in 2022, Michael Ballanger says.

more>

Gold Mining Co. to Trade on TSX.V, Sampling Results Positive (01/11/2022)

Reyna Gold, approved for listing on Toronto's Venture Exchange, finds high-grade gold in samples from La Gloria that highlight the project's potential.

more>

HealthCare Solutions Co. Gains 8 Million New Members in 2021 (01/11/2022)

Accolade Inc. shares rose 27% after the company reported Q3/22 financial results that included a 117% increase in YoY revenue. The firm highlighted that in calendar year 2021, its membership increased four-fold from 2 million to 10 million.

more>

2022 to Be Catalyst Rich for Biopharma (01/10/2022)

The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.

more>

Enrollment Done for COVID-19 Drug Trial (01/10/2022)

Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.

more>

Words With Friends & Grand Theft Auto in Gaming Merger (01/10/2022)

Social gamer Zynga traded 40% higher after the company agreed to be acquired by Take-Two Interactive Inc. in a combination stock and cash transaction for $9.861 per share.

more>

The Critical Investor Shares His Top 7 Picks for 2022 (01/09/2022)

The Critical Investor was asked again by Streetwise Reports to provide his top 7 picks for the new year — at a point where the COVID-19 pandemic is playing out the Omicron variant, inflation is reaching levels not seen in decades, the Fed surprising the markets with a more hawkish stance than anticipated, with metal prices at very high levels although gold and silver seem to be consolidating and setting up for a breakout.

more>

Co.'s samRNA Vaccines Protect Better Against COVID Variants (01/07/2022)

Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.

more>

AI Driven Drug Firm Partners With Merck (01/07/2022)

Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

more>

Logiq Board OKs Splitting Into 2 Companies (01/06/2022)

E-commerce customer acquisition solutions company Logiq Inc. plans to separate into two publicly traded companies this month, President and Executive Chairman Brent Suen says.

more>

2022 Could See Shipping Co. Dividends, Buybacks (01/06/2022)

Noble Capital Markets has an Outperform rating and a $45 per share price target on Euroseas Ltd. given the company's favorable outlook for 2022.

more>

Silver, Gold Could Outperform Industrial Metals in 2022 (01/06/2022)

Mining companies finished 2021 strongly with a 7.3% gain in Q4/21, reported Noble Capital Markets in a research note.

more>

Co. Partners to Test New Cancer Vaccines (01/06/2022)

Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.

more>

Medical Co. Strikes $3B Deal to Buy Digital Care Firm (01/06/2022)

Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash.

more>

Analyst Says Co.'s Stock Could Skyrocket (01/06/2022)

Analyst Clive Maund says Kainantu Resources Ltd.'s stock could take off if it makes a discovery at its properties in Papua New Guinea.

more>

Chen Lin's Top 6 Investment Ideas (01/05/2022)

In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.

more>

New Muscular Dystrophy Drug Shows Promise (01/05/2022)

Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.

more>

Firm to Start Exploration After Survey Results (01/05/2022)

Results of a three-dimensional interpretation of a survey at its Eskay claims could be a major catalyst for Garibaldi Resources, Noble Capital Markets said in a research note.

more>

Co. Plans to Make 100M Rapid COVID Tests Monthly (01/05/2022)

Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.

more>

Tech Growth Pushes Co.'s Rating Higher (01/04/2022)

"We expect strong datacom sales will enable II-VI to exceed Street expectations [in 2022]," noted a Raymond James report.

more>

Oilfield Services Co. Projects 25% Revenue Growth for Q4 (01/04/2022)

Shares of land-focused oil services firm NexTier Oilfield Solutions Inc. traded 27% higher after the company reported it expects Q4/21 revenues will be in the range of $500-510 million and advised that its 32-unit fracking rig fleet will be fully deployed in Q1/22.

more>

Skyharbour Looks to New Uranium Claims (01/03/2022)

Skyharbour Resources Ltd. has staked six new prospective uranium exploration properties within and near the Athabasca Basin of northern Saskatchewan, which contains the world’s highest-grade uranium deposits.

more>

Imperial Helium Expects Its First Sales in 2022 (01/03/2022)

Imperial Helium’s second, future-producing helium well was spud on Dec. 6, 2021, amidst constrained global helium supply. The outlook is good for 2022.

more>

Lead Cancer Drug Gets Fast Tracked (01/03/2022)

Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.

more>

More Archives

2022

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe